[Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study].
Li Bian, Binghe Xu, Lei Di, T Wang, X J Wang, Shunchang Jiao, Jingpu Yang, Zongjing Tong, Jie Liu, J. Feng, D G Liu, Qi Yu, Yinqi Liu, Ye Ma, Hao Yu, Zefei Jiang
Abstract
The recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine has significant efficacy and good safety. It is the optimized therapy regime for patients with taxane-pretreated HER2 positive metastatic breast cancer, which provides more targeted therapy opportunities for HER2 positive breast cancer patients in China.
Topics & Concepts
VinorelbineMedicineMetastatic breast cancerInternal medicineNeutropeniaClinical endpointBreast cancerGastroenterologyAdverse effectRandomized controlled trialSurgeryChemotherapyCancerCisplatinCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies